Woburn, MA – According to filings with the U.S. Securities and Exchange Commission, Abpro is raising $80,000,000.00 in new funding. Sources indicate as part of senior management President, Eugene Chan played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Abpro
Abpro Corporation is a clinical-stage biotechnology company located in Woburn, Massachusetts. The Companys mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpros DiversImmune platform has been used successfully against 300 traditionally difficult targets. The Company has a pipeline of therapies to treat cancer, eye, autoimmune, infectious diseases and other areas.

To learn more about Abpro, visit http://www.abpro-labs.com/

Contact:
Eugene Chan, President
617-225-0808
echan@abpro-labs.com

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved